AzTrials
AzTrials

Carotid Artery DiseaseARMOURNCT00744523

Proximal Protection With The Mo.Ma Device During Carotid Stenting

A study testing Mo.Ma cerebral protection device in people with Carotid Artery Disease, run by Medtronic Endovascular at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Carotid Artery Disease
What is being tested?
Mo.Ma cerebral protection device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
262 participants
Where
2 sitesUnited States
Study dates
Sep 2007to Mar 2009
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

General inclusion criteria Subject meets one or more of the high surgical risk criteria.

  • Subject is ≥ 18 years old.
  • Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach.
  • Subject is willing and able to comply with follow-up evaluations at the specified times.
  • Subject (or legal representative) understands the nature of the procedure and provides informed consent, prior to enrollment in the study.
  • If female subject, is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.

Angiographic inclusion criteria (as determined ≤ 30 days prior to procedure):

  • Target lesion stenosis (% stenosis = (1-N/D) X 100)1, documented by selective angiography pre-intervention, is
  • ≥ 80% stenosis for asymptomatic subjects or
  • ≥ 50% stenosis for symptomatic subjects. Symptomatic is defined as carotid stenosis associated with ipsilateral transient or visual TIA evidenced byamaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral ischemic stroke within 6 months prior to enrollment.
  • Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.
  • External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm.
  • Common carotid artery diameter where the Mo.Ma device will be positioned is 5-13 mm.

General exclusion criteria

  • Subject has participated in, is participating in, or plans to participate in another clinical study that may affect either the pre-procedure or follow-up results.
  • Subject has chronic or paroxysmal atrial fibrillation that is not treated by Coumadin.
  • Subject has undergone prior stenting of the ipsilateral carotid artery.
  • Subject's life expectancy is less than twelve months.
  • Subject is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand.
  • Subject is suffering from dementia.
  • Subject has documented intolerance to BOTH heparin and Angiomax.
  • Subject has an allergy or contraindication to acetylsalicylic acid (ASA).
  • Subject has a documented allergy to the device materials.
  • Subject has a documented allergy to radiographic contrast that cannot be pre-treated.
  • Subject has a documented allergy or contraindication to BOTH clopidogrel and ticlopidine.
  • Subject has had active bleeding diathesis requiring blood transfusion within one (1) month prior to index procedure.
  • Subject has had an MI within 72 hours prior to carotid stenting.
  • Subject has had coronary artery bypass graft (CABG) or vascular surgery within 30 days PRIOR TO index procedure (percutaneous coronary intervention is permissible provided cardiac enzymes are normal within 24 hours of index procedure), OR has planned CABG, vascular surgery, percutaneous coronary intervention (PCI), or has other invasive medical procedures planned within 30 days AFTER index procedure.(Unplanned urgent or emergent procedures may be performed at anytime as clinically indicated).
  • Subject has a major residual neurological deficit (stroke scales: Barthel ≤ 60, NIH ≥ 15 or Rankin > 3) at pre-procedure neurological exam.
  • Subject has had a transient ischemic attack (TIA) or amaurosis fugax within 48 hours prior to index procedure.
  • Subject has had a stroke or retinal artery occlusion within one (1) month prior to index procedure.
  • Subject had abnormal pre-intervention blood counts with platelets < 50,000/cubic mm or > 700,000/cubic mm or white blood cell count < 3,000/cubic mm.
  • Subject has severe chronic renal failure (creatinine > 2.5 mg/dl).
  • Subject is currently being treated for cerebral carcinoma or sarcoma.
  • Subject has peripheral vascular disease, which precludes safe femoral artery sheath insertion.
  • Subject is unable or unwilling to undergo insertion of a temporary pacemaker.

Angiographic exclusion criteria (as determined ≤ 30 days prior to procedure):

  • The target carotid artery is completely occluded.
  • The common carotid artery ostium has stenosis that requires treatment.
  • Multiple carotid stenoses exist in the internal carotid artery (ICA) that cannot be covered by one stent.
  • The presence of ipsilateral intracranial stenosis that requires treatment.
  • The presence of any intracranial tumor(s), arteriovenous malformation(s) (AVMs), or aneurysm(s) requiring treatment.
  • The inability to position a stiff .035" guidewire in the external carotid artery (ECA).
  • Contralateral occlusion of internal carotid artery and vertebral arteries.
  • Aortic arch anatomical anomalies that preclude the safe placement of the device.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • University at Buffalo Neurosurgery

    Buffalo, New York, 14209

  • MidWest Cardiology Research Foundation

    Columbus, Ohio, 43214

Other trials in United States

About this study

Official title: ARMOUR: Proximal Protection With The Mo.Ma Device During Carotid Stenting

The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting

Read the detailed description

Test Device:

Mo.Ma™ Proximal Flow Blockage Cerebral Protection Device. Single size catheter device with a 9 French introducer sheath compatible shaft (outer diameter) and a 6 French compatible working channel (inner diameter), integrating two compliant balloons intended to achieve endovascular clamping of external carotid arteries (ECA) 3-6 mm in diameter and common carotid arteries (CCA) 5-13 mm in diameter.

Primary Objective:

Evaluate the safety and effectiveness of the Mo.Ma device for cerebral protection in the treatment of internal carotid artery (ICA) stenoses, which may or may not involve the bifurcation of the CCA, in subjects considered to be at high surgical risk for complications during carotid endarterectomy (CEA).

Primary Endpoint:

Major adverse cardiac and cerebrovascular events (MACCE) within 30 days of implantation. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.

Being tested
Mo.Ma cerebral protection device
Keywords
carotid artery stenting, stroke, cerebral protection, high surgical risk
Medical subject headings
Carotid Artery Diseases, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mo.Ma cerebral protection deviceDevice

    Also called Mo.Ma

    Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.

Study groups in NCT00744523
Study groupRoleWhat they receive
Mo.ma cerebral protection deviceExperimentalMo.Ma cerebral protection device
Receives: Device: Mo.Ma cerebral protection device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure.

    Number of subjects with one or more Major Adverse Cardiac and Cerebrovascular Events through 30 days after the procedure. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.

    Measured: Up to 30 days after the procedure was performed

Secondary outcomes (6)
  1. Device Success

    Number of subjects in which the MO.MA was able to be positioned, deployed, and retrieved intact during the index procedure.

    Measured: The entire duration of the index procedure

  2. Technical Success

    Number of subjects with device success and the ability to successfully implant a carotid stent and obtain a residual stenosis < 30% during the index procedure(as evaluated by the angiographic core laboratory).

    Note: Three subjects were missing final angiographic results and therefore Technical and Procedural success could not be defined for these three subjects, thereby, decreasing the number of participants analyzed from 225 to 222.

    Measured: The entire duration of the index procedure

  3. Procedural Success

    Number of subjects with technical success without the occurrence of any MACCE or unresolved antegrade flow blockage intolerance during the index hospitalization.

    Note: Three subjects were missing final angiographic results and therefore Technical and Procedural success could not be defined for these three subjects, thereby, decreasing the number of participants analyzed from 225 to 222.

    Measured: The entire duration of the index procedure through hospital discharge

  4. Restenosis at 30 Days

    Number of subjects with re-narrowing of the lesion at 30 days as defined as a >= 50% stenosis measured by duplex ultrasound scan.

    Measured: Up to 30 days after the procedure was performed

  5. Target Lesion Revascularization at 30 Days

    Number of subjects with any repeat invasive procedure, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase lumen diameter inside or within 10 mm of the previously treated lesion.

    Measured: Up to 30 days after the procedure was performed

  6. Access Site Adverse Events

    Number of subjects with adverse events at the percutaneous access site as a result of the index procedure, including bruising, hematoma and bleeding requiring treatment by transfusion of blood products, surgical repair, ultrasound compression or thrombin injection.

    Measured: Index Procedure through Hospital Discharge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2008 (estimated)
  2. Study startSep 2007
  3. Primary completionMar 2009
  4. Study completionMar 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
262 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00744523
Sponsor's protocol ID
P-2850
Acronym
ARMOUR
Status last verified
Jan 2016
First submitted
29 Aug 2008
Last updated
26 Feb 2016
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Mo.Ma cerebral protection device in people with Carotid Artery Disease, run by Medtronic Endovascular at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 May 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure. (time frame: Up to 30 days after the procedure was performed). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in